afimetoran], and Alzheimer's disease [Anti-MTBR Tau]. Now, dear Seeking Alpha readers, I want to draw your attention to the ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Emraclidine, a once-daily medication in development for schizophrenia and Alzheimer's disease psychosis, was the main focus AbbVie's acquisition of Cerevel, which closed earlier this year. The setback ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... These drugs are also being tested for Alzheimer’s and other conditions commonly linked to obesity.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Bristol Myers Squibb continues to enroll the ongoing Phase 2 clinical trial in approximately 475 patients with early Alzheimer's disease; primary completion expected in 2027 (NCT06268886) Bristol ...

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.